Univariate Cox regression analysis of variables investigated as potential predictors of TFR
| Variable . | No. of patients . | Univariate analysis at 24 mo . | No. of patients . | Univariate analysis at 60 mo . | ||||
|---|---|---|---|---|---|---|---|---|
| β coefficient . | Hazard ratio (95% CI) . | P . | β coefficient . | Hazard ratio (95% CI) . | P . | |||
| Gender | 40 | 40 | ||||||
| Male | 19 | Ref | 19 | Ref | ||||
| Female | 21 | 0.111 | 1.117 (0.462-2.702) | .806 | 21 | 0.17 | 1.185 (0.519-2.707) | .687 |
| Age at TFR attempt, y | 40 | 0.026 | 1.027 (0.986-1.069) | .196 | 40 | 0.017 | 1.017 (0.981-1.055) | .36 |
| Sokalscore | 36 | 36 | ||||||
| High | 8 | Ref | 8 | Ref | ||||
| Intermediate | 14 | 0.94 | 2.56 (0.695-9.432) | .158 | 14 | 0.753 | 2.123 (1.264-0.206) | .206 |
| Low | 14 | −0.104 | 0.901 (0.215-3.784) | .887 | 14 | −0.164 | 0.849 (0.236-3.049) | .802 |
| EUTOS score | 36 | 36 | ||||||
| High | 4 | Ref | 4 | Ref | ||||
| Low | 32 | −0.08 | 0.923 (0.211-4.045) | .915 | 32 | −0.296 | 0.744 (1.214-2.588) | .642 |
| Transcript type | 40 | 40 | ||||||
| e13a2 | 16 | Ref | 16 | Ref | ||||
| e14a2 | 18 | −1.106 | 0.331 (0.117-0.980) | .046 | 18 | −0.86 | 0.423 (0.162-0 1.103) | .078 |
| Both e13a2 and e14a2 | 6 | 0.435 | 1.544 (0.525-4.542) | .43 | 6 | 0.398 | 1.49 (0.511-4.340) | .465 |
| Duration of TKI therapy | 40 | 0.019 | 1.02 (0.913-1.139) | .731 | 40 | 0.03 | 1.031 (0.927-1.146) | .579 |
| Duration of MR4, y | 40 | −0.027 | 0.973 (0.807-1.174) | .971 | 40 | −0.005 | 0.995 (0.837-1.183) | .955 |
| Duration of MR4.5, y | 40 | −0.11 | 0.896 (0.719-1.116) | .327 | 40 | −0.078 | 0.925 (0.756-1.131) | .448 |
| TKI ceased | 40 | 40 | ||||||
| Dasatinib | 13 | Ref | 13 | Ref | ||||
| Imatinib | 13 | −0.466 | 0.628 (0.223-1.766) | .377 | 13 | −0.434 | 0.648 (0.238-1.765) | .396 |
| Nilotinib | 14 | −0.678 | 0.508 (0.17-1.516) | .224 | 14 | −0.533 | 0.587 (0.214-1.610) | .301 |
| Halving time, d | 37 | 0.072 | 1.074 (0.991-1.165) | .084 | 37 | 0.083 | 1.086 (1.006-1.173) | .034 |
| Leukocytes, BCR::ABL1 pos∗ | 39 | 1.258 | 3.519 (1.025-12.08) | .046 | 39 | 1.407 | 4.084 (1.201-13.89) | .024 |
| Granulocytes, BCR::ABL1 pos∗ | 40 | 2.158 | 8.654 (3.241-23.11) | .00002 | 40 | 1.871 | 6.494 (2.61-16.16) | .00006 |
| Monocytes, BCR::ABL1 pos∗ | 37 | 0.299 | 1.349 (0.531-3.426) | .529 | 37 | 0.243 | 1.28 (0.524-3.104) | .592 |
| B cells, BCR::ABL1 pos∗ | 38 | 0.035 | 1.0353 (0.3-3.568) | .956 | 38 | 0.113 | 1.119 (0.328-3.82) | .857 |
| T cells, BCR::ABL1 pos∗ | 39 | 1.165 | 3.206 (1.068-9.621) | .038 | 39 | 1.458 | 4.297 (1.246-14.82) | .021 |
| NK cells, BCR::ABL1 pos∗ | 37 | 0.01 | 1.01 (0.396-2.576) | .984 | 37 | 0.06 | 1.061 (0.421-2.676) | .9 |
| Variable . | No. of patients . | Univariate analysis at 24 mo . | No. of patients . | Univariate analysis at 60 mo . | ||||
|---|---|---|---|---|---|---|---|---|
| β coefficient . | Hazard ratio (95% CI) . | P . | β coefficient . | Hazard ratio (95% CI) . | P . | |||
| Gender | 40 | 40 | ||||||
| Male | 19 | Ref | 19 | Ref | ||||
| Female | 21 | 0.111 | 1.117 (0.462-2.702) | .806 | 21 | 0.17 | 1.185 (0.519-2.707) | .687 |
| Age at TFR attempt, y | 40 | 0.026 | 1.027 (0.986-1.069) | .196 | 40 | 0.017 | 1.017 (0.981-1.055) | .36 |
| Sokalscore | 36 | 36 | ||||||
| High | 8 | Ref | 8 | Ref | ||||
| Intermediate | 14 | 0.94 | 2.56 (0.695-9.432) | .158 | 14 | 0.753 | 2.123 (1.264-0.206) | .206 |
| Low | 14 | −0.104 | 0.901 (0.215-3.784) | .887 | 14 | −0.164 | 0.849 (0.236-3.049) | .802 |
| EUTOS score | 36 | 36 | ||||||
| High | 4 | Ref | 4 | Ref | ||||
| Low | 32 | −0.08 | 0.923 (0.211-4.045) | .915 | 32 | −0.296 | 0.744 (1.214-2.588) | .642 |
| Transcript type | 40 | 40 | ||||||
| e13a2 | 16 | Ref | 16 | Ref | ||||
| e14a2 | 18 | −1.106 | 0.331 (0.117-0.980) | .046 | 18 | −0.86 | 0.423 (0.162-0 1.103) | .078 |
| Both e13a2 and e14a2 | 6 | 0.435 | 1.544 (0.525-4.542) | .43 | 6 | 0.398 | 1.49 (0.511-4.340) | .465 |
| Duration of TKI therapy | 40 | 0.019 | 1.02 (0.913-1.139) | .731 | 40 | 0.03 | 1.031 (0.927-1.146) | .579 |
| Duration of MR4, y | 40 | −0.027 | 0.973 (0.807-1.174) | .971 | 40 | −0.005 | 0.995 (0.837-1.183) | .955 |
| Duration of MR4.5, y | 40 | −0.11 | 0.896 (0.719-1.116) | .327 | 40 | −0.078 | 0.925 (0.756-1.131) | .448 |
| TKI ceased | 40 | 40 | ||||||
| Dasatinib | 13 | Ref | 13 | Ref | ||||
| Imatinib | 13 | −0.466 | 0.628 (0.223-1.766) | .377 | 13 | −0.434 | 0.648 (0.238-1.765) | .396 |
| Nilotinib | 14 | −0.678 | 0.508 (0.17-1.516) | .224 | 14 | −0.533 | 0.587 (0.214-1.610) | .301 |
| Halving time, d | 37 | 0.072 | 1.074 (0.991-1.165) | .084 | 37 | 0.083 | 1.086 (1.006-1.173) | .034 |
| Leukocytes, BCR::ABL1 pos∗ | 39 | 1.258 | 3.519 (1.025-12.08) | .046 | 39 | 1.407 | 4.084 (1.201-13.89) | .024 |
| Granulocytes, BCR::ABL1 pos∗ | 40 | 2.158 | 8.654 (3.241-23.11) | .00002 | 40 | 1.871 | 6.494 (2.61-16.16) | .00006 |
| Monocytes, BCR::ABL1 pos∗ | 37 | 0.299 | 1.349 (0.531-3.426) | .529 | 37 | 0.243 | 1.28 (0.524-3.104) | .592 |
| B cells, BCR::ABL1 pos∗ | 38 | 0.035 | 1.0353 (0.3-3.568) | .956 | 38 | 0.113 | 1.119 (0.328-3.82) | .857 |
| T cells, BCR::ABL1 pos∗ | 39 | 1.165 | 3.206 (1.068-9.621) | .038 | 39 | 1.458 | 4.297 (1.246-14.82) | .021 |
| NK cells, BCR::ABL1 pos∗ | 37 | 0.01 | 1.01 (0.396-2.576) | .984 | 37 | 0.06 | 1.061 (0.421-2.676) | .9 |
Significant P values are shown in bold.
CI, confidence interval; EUTOS, European Treatment and Outcome Study; pos, positive; ref, reference.
Binary variables.